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The Antiarrhythmic Effect of Nortriptyline in Cardiac Patients With 
Ventricular Premature Depolarizations 
ELSA-GRACE V, GIARDINA, MD, FACC, THOMAS BARNARD, MD, LYNNE JOHNSON, MD, 
ALAN L. SAROFF, MD, FACC, J. THOMAS BIGGER, JR., MD, FACC, MAY LOUIE, BA 
The effect of nortriptyline against ventricular arrhyth-
mias was determined in 16 cardiac patients with 30 or 
more ventricular premature depolarizations per hour. 
Nortriptyline was administered orally, 0.5 mg/kg body 
weight per day, and increased by 0.5 mg/kg per day 
every third day until ventricular premature depolari-
zations were suppressed (2:80%), adverse effects oc-
curred or a total daily dose of 3.5 mg/kg per day was 
given. Each patient had daily 24 hour continuous elec-
trocardiograms, 12 lead standard electrocardiograms and 
physical examination; blood pressure was measured in 
the supine and standing position four times a day. Each 
patient also had radionuclide angiography at rest to mea-
sure ejection fraction before and at the effective or max-
Recently, the tricyclic antidepressant imipramine has been 
reported to be an effective clinical antiarrhythmic agent 
against chronic stable ventricular premature depolarizations 
(l ,2) as well as sustained ventricular arrhythmias (3). How-
ever, symptomatic orthostatic changes have been associated 
with the use of imipramine, particularly at high plasma drug 
concentrations (4,5), in severely depressed patients (4), in 
the elderly (6) and in patients with preexisting orthostatic 
hypotension (7). Cardiac patients at risk for orthostatic changes 
include those taking antihypertensive drugs or preload- and 
afterload-reducing agents including nitrates or calcium channel 
antagonists. Studies in psychologically depressed patients 
(8-10) indicate that the tricyclic antidepressant nortriptyline 
is not associated with significant orthostatic hypotension. If 
nortriptyline is also antiarrhythmic, patients with ventricular 
premature depolarizations could benefit from it, particularly 
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imal dose. Thirteen patients (81 %) had an antiar-
rhythmic response and 11 met the study criterion of at 
least 80% improvement. Doses ranged from 50 to 200 
mg/day (mean 111 ± 45), steady state plasma concen-
tration ranged from 46 to 410 ng/ml (mean 153 ± 96) 
and half-life of elimination of nortriptyline was 4 to 22 
hours (mean 13 ± 4). Administration of nortriptyline 
did not depress mean ejection fraction (before 42 ± 
12%, after 41 ± 12%); it was associated with an or-
thostatic decrease in systolic blood pressure (mean-13 
± 13 mm Hg). Nortriptyline is an effective antiar-
rhythmic agent which may be given twice a day even in 
patients with impaired ventricular function. 
() Am Coll CardioI1986;7:1363-9) 
those intolerant of or sensitive to orthostatic blood pressure 
changes. 
This study had three goals: I) to evaluate the antiar-
rhythmic and electrocardiographic effect of nortriptyline in 
patients with stable ventricular premature depolarizations, 
2) to assess the effects of nortriptyline on ejection fraction 
and blood pressure, and 3) to determine the therapeutic 
antiarrhythmic plasma concentration range of nortriptyline. 
Methods 
Study patients. Sixteen patients with 30 or more ven-
tricular premature depolarizations per hour referred by their 
primary physician enrolled. After signing informed consent 
approved by the Institutional Review Board of the Colum-
bia-Presbyterian Medical Center, each was hospitalized in 
the General Clinical Research Center for the study. Each 
patient underwent the following: history and physical ex-
amination, 12 lead electrocardiogram, chest Xray, mea-
surement of blood sugar, blood urea nitrogen, serum elec-
trolytes, cholesterol and antinuclear antibody titer, liver 
function studies and lupus erythematosus cell preparation. 
Patients were excluded if they had had an acute myocardial 
infarction within 3 months of enrollment or sustained ven-
tricular arrhythmias or uncontrolled left ventricular failure. 
0735-10971861$3 50 
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Administration of other antiarrhythmic drugs was discon-
tinued at least 48 hours before entry into the study. 
Sixteen consecutive cardiac patients enrolled: 12 women 
and 4 men ranging in age from 30 to 74 years (mean 59 ± 
15) (Table 1). All patients had heart disease, including ar-
teriosclerosis (7 patients), cardiomyopathy (5 patients), hy-
pertension (2 patients), primary electrical abnormality (1 
patient) and mitral valve prolapse (1 patient). Thirteen were 
in New York Heart Association functional class I or II and 
3 were in class III or IV. Twelve patients had been treated 
with one to three antiarrhythmic drugs before treatment with 
nortriptyline and 13 were taking medications, including flur-
azepam hydrochloride (6 patients), digoxin (4 patients), 
thiazide (1 patient), terbutaline (1 patient), prednisone (1 
patient), clonidine hydrochloride (1 patient) and propran-
olol, 10 mg three times a day (1 patient). Digoxin concen-
tration measured before the start of nortriptyline adminis-
tration ranged from 0.5 to 1.3 ng/ml (mean 0.84 ± 0.30), 
and after administration it ranged from 0.5 to 1.2 ng/ml 
(mean 0.83 ± 0.24) (p = NS). 
Short-term dosing protocol. During each day of short-
term dose ranging, patients had a 24 hour continuous elec-
trocardiogram to assess heart rate and frequency of ven-
tricular premature depolarizations and to measure electro-
cardiographic intervals. After a drug-free day and a placebo 
day, dosing was started with nortriptyline (Aventyl), 0.5 
mg/kg body weight per day (to the nearest 25 mg) given 
orally in two divided doses. Nortriptyline and placebo were 
supplied by Eli Lilly Research Laboratories. The dose was 
increased by 0.5 mg/kg per day after every third day, that 
is, after six doses, until: 1) at least 80% suppression of 
ventricular premature depolarizations was observed (the ef-
Table 1. Clinical Characteristics of 13 Patients 
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fective dose), which was arbitrarily selected as the end point 
for efficacy (11), 2) adverse drug effects were noted, or 3) 
a total of 3.5 mg/kg per day of nortriptyline was given. The 
decision to increase the daily dose was made after one in-
vestigator had scanned the 24 hour electrocardiographic re-
cordings on an Avionics scanner (model 660A). Later, com-
puter analysis was used to determine the frequency of ven-
tricular premature depolarizations, complex features and heart 
rate. 
Ejection fraction. Radionuclide ejection fraction was 
measured at supine rest before and while the patient was 
receiving the effective or maximal dose. Angiocardiography 
was performed by the first pass technique with technetium-
99 pertechnetate using a computerized multiple-crystal scin-
tillation camera (Baird-Atomic System 77). Ejection frac-
tion was determined using a modification of the method of 
Marshall et al. (12). Validation of this method against con-
trast ventriculography has been reported (3). Studies were 
interpreted by one investigator who did not know the ex-
amination order, and results were determined at the same 
time of day in each patient, 2 to 4 hours after the morning 
dose. 
Blood pressure. Blood pressure was measured at rest 
(supine) and after 2 minutes of quiet standing four times a 
day. The mean ± SD of the supine and standing systolic 
and diastolic blood pressures was determined for each pa-
tient on each day. Blood pressure on the placebo day was 
compared with the effective dose or the maximal dose for 
nonresponders. 
Plasma drug concentration. On the second and third 
days after a dose change, plasma was collected just before 
at "trough" and 2 hours after a dose. When the effective 
New York Heart Association 
Case Age (yr) & Sex 
1 30F 
2 47F 
3 74F 
4 42F 
5 68M 
6 62F 
7 58M 
8 53F 
9 4lF 
10 70F 
11 73M 
12 40F 
13 68F 
14 73M 
15 74F 
16 74F 
Mean ± SD 59 ± IS 
Etiology Functional Class 
MVP 
CMP 
ASCVD II 
CMP I 
ASCVD II 
CMP III 
ASCVD II 
ASCVD III 
ASCVD 
ASCVD II 
ASCVD II 
CMP III 
CMP 
HCVD II 
HCVD 
PEA 
Symptoms 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
Ineffective 
Prior Treatment 
PA,Q 
PA,Q 
PA,Q 
PA 
PA,Q,Diso 
PA,Q,Diso 
PA,Q 
PA,Q,Diso 
PA,Q 
PA,Q 
PA,Q,Diso 
PA 
ASCVD = arteriosclerotic heart disease; CMP = cardIomyopathy; Dlso = disopyramide; F == female; HCVD == hypertenSIve cardiovascular 
disease; M = male; MVP = mitral valve prolapse; PA = procainamide; PEA = primary electrical abnormality; Q = quinidine; + = present; - == 
absent. 
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or maximal dose was reached, blood was collected at 2. 4, 
6, 8, 10 and 12 hours after drug administration to determine 
plasma nortriptyline concentration. Because patients re-
ceived each dose for at least 3 days, steady state concen-
trations (90%) were expected when samples were collected. 
Nortriptyline was measured by a gas chromatographic method 
(14) and results were reported as nanogram per milliliter 
base. The elimination constant (kel) of the least squares fit 
of the terminal portion of the time-log concentration plot 
was calculated (elimination half-life = 0.693/kel). Average 
steady state plasma concentration was determmed by mea-
suring the area under the curve of the plasma concentration 
time course by the trapezoidal rule (15). 
Statistical analysis. Statistical analysis was determined 
using the BMDP software package (1983 edition). The sig-
nificance of electrocardiographic changes, frequency of ven-
tricular arrhythmia, ventricular function and blood pressure 
was tested by analysis of variance. Ventricular premature 
depolarizations and complex features were analyzed after a 
log transformation of frequency data. A probability (p) value 
of less than 0.05 was considered statistically significant. 
Data are reported as mean ± SD. 
Results 
Effect on ventricular premature depolarizations and 
complex features (Table 2). All 16 patients had two base-
line 24 hour electrocardiograms before dose ranging; ar-
rhythmia frequency was computed as the mean of the fre-
quencies measured on recordings obtained in the drug-free 
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state and during placebo administration. Before nortriptyline 
administration, the frequency of ventricular premature de-
polarizations ranged from 31 to 2,273 per hour (mean 578 
± 719), episodes of pairs ranged from 1 to 3,069 (mean 
295 ± 753), and episodes of non sustained ventricular tachy-
cardia ranged from 0 to 705 (mean 64 ± 175). 
Nortriptyline had an antiarrhythmic effect in 13 patients 
(81 %) (p < 0.05), the study criterion (2::80% improvement) 
was met in 11, more than 65% improvement was recorded 
in 2 and less than 40% improvement was recorded in 3. 
Nortriptyline was very effective against complex features: 
pairs were abolished in 11 of 16 patients (p < 0.05), and 
were suppressed by 87 to 98% in 3 patients and by 43% in 
1 patient. Ventricular tachycardia was completely sup-
pressed in 9 of 11 patients (p < 0.05), was suppressed by 
98% in 1 patient and was not suppressed in 1 patient with 
one episode of nonsustained ventricular tachycardia (three 
complexes). 
A prolonged antiarrhythmic effect was documented by 
means of 24 hour electrocardiographic monitoring in pa-
tients who responded after dose ranging. Two responders 
withdrew after 4 weeks because of urinary hesitancy (Case 
14) and confusion (Case 11) and one patient was lost to 
follow-up (Case 3) and did not have arrhythmia evaluation. 
Arrhythmia was evaluated on at least one occasion in nine 
patients (mean 1.9 occasions, range 1 to 3) at a mean of 
27 ± 22 weeks (range 4 to 52) of follow-up. At the foIlow-
up evaluation, there was 88 ± 20% (range 27 to 100%) 
suppression of ventricular premature depolarizations. 
Effect on electrocardiographic intervals. Nortrip-
tyline caused a slight increase in heart rate and PR, QRS 
Table 2. Effect of Nortnptyline on Ventricular Premature Depolarizations per Hour, Pairs and Ventricular Tachycardia 
VPOs per Hour Episodes of Pairs Ventricular Tachycardia 
Case Predrug* Postdrug % Predrug* Postdrug % Predrug* Postdrug % 
78 I 99 0 100 0 0 
2 420 0 100 0 100 0 0 
3 75 14 81 54 98 I I 0 
4 112 84 25 188 108 43 5 0 100 
5 31 21 32 4 4 0 0 0 
6 1,161 6 99 173 0 100 141 0 100 
7 2,273 10 99 3,069 0 100 705 0 100 
8 36 12 67 4 0 100 0 0 
9 152 6 96 14 0 100 2 0 100 
10 1,918 65 97 202 0 100 37 0 100 
II 85 12 86 14 0 100 0 0 
12 294 187 36 493 64 87 84 2 98 
13 341 I 99 350 0 100 12 0 100 
14 53 14 74 42 2 95 6 0 100 
15 1,042 10 99 57 0 100 9 0 100 
16 1,178 3 99 46 0 100 32 0 100 
Mean 578 28 81 295 II 89 64 0 91 
:': SO :': 719 :': 48 :':27 :': 753 + 30 ± 28 ± 175 ± 0.5 ± 30 
*Mean of two 24 hour electrocardiographic recording~. VPOs = ventncular premature depolarizations; % = percent improvement over predrug 
level. 
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Table 3. Ejection Fraction and Blood Pressure Before and After Nortriptyline 
EjectIOn Fraction (%) Blood Pre,sure (mm Hg) OrthostatIc Change (mm Hg) 
Ca,e Before After Before After Systolic DiastolIc 
47 46 130/100 120/82 -10 -18 
2 49 49 94170 95/80 +1 + 10 
3 38 38 
4 46 53 124/80 112/92 -12 +8 
5 30 26 120175 95170 -25 -5 
6 25 33 131180 116/84 -15 +4 
7 33 30 128175 97172 -30 -3 
8 45 41 130/84 100178 -20 -6 
9 60 54 121180 111183 -11 +3 
10 39 41 123170 121175 -2 +5 
11 49 55 130/85 110178 -20 -7 
12 15 14 85/63 79/55 -6 -8 
13 35 32 126/83 94169 -32 -14 
14 54 44 160/85 130/80 -30 -5 
15 54 49 182/92 182/110 0 + 18 
16 52 53 90160 100170 +10 +10 
Mean ± SD 42 ± 12 41 ± 12 125179 ± 25/10 111179 ± 24/12 - \3 ± 13 -0.5 ± 10 
and QTc intervals (p = NS). Mean heart rate was 84 ± 
II beats/min before nortriptyline and 88 ± 11 beats/min 
after nortriptyline; mean PR interval before nortriptyline was 
177 ± 26 ms and 189 ± 28 ms after nortriptyline; mean 
QRS interval before nortriptyline was 94 ± 18 ms and 98 
± 18 ms after nortriptyline; mean QTc interval before nor-
triptyline was 438 ± 33 ms and 445 ± 31 ms after nor-
triptyline. 
Effect on left ventricular function (Table 3). The ejec-
tion fraction in the 13 patients was normal to severely de-
pressed before (range 15 to 60%, mean 42 ± 12) and after 
(range 14 to 55%, mean 41 ± 12) nortriptyline (p = NS). 
Effect on orthostatic blood pressure (Table 3). There 
was no significant change in supine systolic or diastolic 
blood pressure after nortriptyline. All patients except two 
had a decrease in standing systolic blood pressure after 
nortriptyline. Before nortriptyline. mean standing systolic 
blood pressure was 125 ± 25 mm Hg and after nortriptyline 
it was 111 ± 24 mm Hg. Mean orthostatic change in systolic 
blood pressure was -13 ± 13 mm Hg (p = NS). There 
was no significant change in standing diastolic blood pres-
sure after nortriptyline. Three patients who had more than 
30 mm Hg orthostatic change tolerated the blood pressure 
change without symptoms. However, one who had severely 
impaired ventricular function. with an ejection fraction of 
15% and a predrug blood pressure of 85/63 mm Hg, had 
orthostatic symptoms when the systolic blood pressure was 
75 mm Hg; dose ranging was discontinued in this patient. 
Doses and half-life of elimination (Table 4). The dose 
of nortriptyline administered ranged from 50 to 200 mg/day 
(mean 111 ± 45). More than half of the patients responded 
at less than 125 mg/day; days to reach efficacy ranged from 
1 to 12 days (mean 6 ± 3.5). 
There was interindividual variability in plasma nortrip-
tyline concentration and peak nortriptyline concentration 
ranged from 78 to 600 ng/ml (mean 233 ± 136). Average 
steady state plasma concentration (:2:80% suppression) ranged 
from 46 to 410 ng/ml (mean 153 ± 96). Figure 1 shows 
the linear log concentration-probit relation for nine re-
sponders. The concentration at which 50% of patients (probit 
5) respond is 120 ng/m!. 
Interindividual variability between arrhythmia suppres-
Table 4. Dose, Peak Concentration, Steady State Concentration 
and Half-Life of Elimination of Nortriptyline 
Concentratton (ng/ml) 
Elimination 
Dose Steady Half-life 
Case (mg) Peak State (h) 
1 100 316 258 17 
2 50 288 154 12 
3 75 * * * 
4 125 83 46t 10 
5 125 250 126t 4 
6 50 92 59 12 
7 150 * * -* 
8 150 245 125t 14 
9 150 239 155 8 
10 150 600 410 17 
11 100 78 47 14 
12 100 169 132t 12 
13 50 149 106 10 
14 200 333 226t 14 
15 100 156 131 22 
16 125 258 162 14 
Mean III 233 153 13 
± SD ± 45 ± 136 ± 96 ± 4 
*Blood samples were not collected; t did not achieve> 80% efficacy. 
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sion and plasma nortriptyline concentration was observed, 
The response-concentration relation was plotted for re-
sponders who had at least two 24 hour electrocardiographic 
recordings and corresponding plasma concentrations before 
efficacy was achieved (Fig, 2), Percent change in ventricular 
premature depolarizations was measured by comparing the 
frequency on 24 hour electrocardiographic recordings during 
treatment with the baseline frequency. Percent change in 
concentration was determined by comparing treatment 
"trough" nortriptyline concentration with the average steady 
state concentration (see Methods). In three patients, marked 
early improvement was associated with relatively small 
changes in concentration within 2 to 3 days. Further changes 
in concentration did not alter efficacy. In three others, there 
was progressive improvement over 7 to 8 days. It is possible 
that ventricular premature depolarizations that are sup-
pressed early, concordant with slight concentration changes, 
are more uniform or reside in a homogeneous or rapidly 
equilibrating compartment. 
The mean half-life of nortriptyline (parent compound) 
ranged from 4 to 22 hours (mean 13 ± 4). In one patient 
in whom the half-life of nortriptyline was 4 hours, efficacy 
was not reached and an adverse effect limited dose ranging. 
The possibility that the short half-life contributed to inad-
equate drug concentration over the dosing interval was con-
sidered. There was no relation between age, ejection fraction 
or functional class and half-life of elimination. 
Adverse effects. Symptoms associated with tricyclic 
antidepressants were observed in 13 patients. These in-
cluded dry mouth (11 patients), weight gain (4 patients), 
constipation (3 patients) and urinary hesitancy (2 patients). 
One patient gained 10 pounds and requested that nortrip-
Figure 1. The linear log concentration-probit relation for nine 
responders. The concentration at which 50% (probit 5) respond 
with efficacy (2:80%) is 120 ng/m!. 
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Figure 2. The response-concentration relation between percent 
change in frequency of ventricular premature depolarizations (VPD) 
and percent change in plasma nortriptyline concentration. A, Re-
sponse of three patients who had a relatively early improvement 
associated with small changes in plasma concentration. In these 
three, further increase in concentration was not associated with 
further changes in arrhythmia frequency. B, Responses of three 
other patients who had progressive but variable improvement as-
sociated with more slowly changing plasma drug concentration. 
tyline be withdrawn after 24 weeks. Weight gain was not 
associated with edema or left ventricular failure, but was 
characterized by carbohydrate craving and increased oral 
intake. Carbohydrate craving has been reported after ami-
triptyline and nortriptyline without abnormalities of insulin 
or glucose intolerance (16,17). Two other patients with uri-
nary hesitancy had 67 and 74% improvement, respectively; 
these patients continued nortriptyline for 52 and 4 weeks, 
respectively. 
Bothersome adverse effects, observed in four patients, 
included confusion (two patients), hypotension (one pa-
tient), ataxia (one patient) and sinus tachycardia (one pa-
tient). Treatment was discontinued in three patients during 
dose ranging because of confusion (one patient), hypoten-
sion (one patient) and sinus tachycardia (one patient). Two 
others had treatment discontinued after 4 weeks because of 
confusion and ataxia (one patient) and urinary hesitancy (one 
patient). The overall duration of treatment was 32 ± 24 
weeks. 
The overall relation between toxic and therapeutic levels 
could not be established, in part because of interindividual 
variability in plasma nortriptyline concentration. Anticho-
linergic effects, dry mouth and constipation in particular, 
were noted within 2 to 4 days and were not related to dose 
level or plasma nortriptyline concentration. 
Discussion 
Antiarrhythmic effect. For more than 20 years, it had 
been thought that tricyclic antidepressants were contrain-
dicated in patients with arrhythmias and that they could be 
arrhythmogenic. This concept resulted from observations of 
sinus tachycardia, arrhythmias and hypotension after severe 
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tricyclic agent overdose (8,18). More recent studies (1-3) 
indicate that at least one tricyclic antidepressant, imipra-
mine, has electrophysiologic and antiarrhythmic effects sim-
ilar to those of type I antiarrhythmic drugs. In this study, 
we observed that nortriptyline is also antiarrhythmic in non-
depressed cardiac patients with ventricular premature de-
polarizations. To what extent other tricyclic antidepressants 
produce antiarrhythmic effects is not clear and requires in-
vestigation. 
In vitro and clinical studies indicate that nortriptyline has 
electrophysiologic effects similar to those of conventional 
type I antiarrhythmic drugs and the tricyclic antidepres-
sants imipramine (19,20) and doxepin (21). In canine Pur-
kinje fibers, nortriptyline increases conduction time, sup-
presses automaticity, reduces the slope of phase 4 in oua-
bain-toxic fibers and abolishes ouabain-induced afterpotentials; 
moreover, very high concentrations are associated with sig-
nificant depression of membrane responsiveness (22). Vohra 
et a!. (23) noted that PR and QRS intervals were prolonged 
when average plasma nortriptyline concentration was 182 
ng/ml and found that the HV interval was significantly pro-
longed in four of five patients when the plasma concentration 
was more than 200 ng/m!. 
Plasma concentration. Studies in depressed patients 
(24,25) indicate that the antidepressant effect of nortripty-
line correlates with plasma concentration and that the anti-
depressant plasma concentration range is 50 to 150 ng/m!. 
In the present study, the antiarrhythmic drug concentration 
range was higher, ranging from 46 to 410 ng/m!. Interin-
dividual variability in plasma nortriptyline concentration was 
noted, which could be attributed to the level of the dose, 
the age of the patient (26) and the rate of elimination and 
metabolism including hydroxylation (24,25) to the uncon-
Figure 3. The average hourly percent suppression of ventricular 
premature depolarizations (VPD) for II patients who had im-
provement (2:80%) after the morning and evening dose of nor-
triptyline (arrows). The horizontal black line indicates the cri-
terion of efficacy (2:80%). 
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jugated form of the major nortriptyline metabolite, lO-hy-
droxynortriptyline (27). 
In depressed patients, nortriptyline is administered once 
or twice a day because of its long half-life and prolonged 
duration of action. In addition to a relatively long mean 
half-life of elimination (13 ± 4 hours), nortriptyline's anti-
arrhythmic effect was sustained over the 12 hour dosing 
interval (Fig. 3). That lO-hydroxynortriptyline or other me-
tabolites contribute to the sustained antiarrhythmic effect is 
a consideration. Along these lines, the metabolites of imip-
ramine have cardiac effects; for example, desmethylimip-
ramine produces identical electrocardiographic changes (28), 
and 2-hydroxyimipramine and 2-hydroxydesmethylimipra-
mine are also cardioactive (29-31). 
Left ventricular function and blood pressure. Studies 
in patients with cardiac disease indicate that imipramine 
(4,32) and doxepin (32) do not have an adverse effect on 
ventricular function, even when function is moderately to 
severely impaired. Nortriptyline did not affect mean ven-
tricular performance at rest in our study. That it may di-
minish arterial resistance to account for orthostatic blood 
pressure changes was considered. If nortriptyline decreases 
peripheral resistance, an increase in ejection fraction, rather 
than no change, might be expected. Although standing sys-
tolic blood pressure falls after nortriptyline, (supine) systolic 
and diastolic blood pressure do not. From our radionuclide 
studies at rest, it cannot be inferred that nortriptyline has 
an afterload-reducing effect or masks a negative effect on 
cardiac output. However, myocardial performance does not 
exhibit depression, even in patients with severe impairment, 
when rest and exercise radionuclide angiograms are eval-
uated after administration of imipramine or doxepin (4,32). 
Several studies indicate that nortriptyline does not cause 
significant orthostatic effects and may provide an alternative 
for patients predisposed to orthostatic effects or symptoms. 
Three reports (8-10) comparing nortriptyline with imipra-
mine found that nortriptyline did not adversely affect the 
blood pressure of elderly, depressed, hospitalized patients, 
whereas imipramine was associated with orthostatic hypo-
tension in 20%. However, Reed et a!. (33) examined eight 
patients and noted orthostatic changes after nortriptyline, 
that is, a mean postdrug change of 24 mm Hg versus a mean 
predrug change of 10 mm Hg, which is comparable with 
our findings. It should be noted that nortriptyline has not 
been compared with other tricyclic antidepressants regarding 
its antiarrhythmic or hemodynamic effects in cardiac pa-
tients . 
Conclusions. Nortriptyline is a very effective antiar-
rhythmic agent with a long half-life of elimination allowing 
twice a day dosing. Although orthostatic changes were well 
tolerated in the study group, potentially profound effects 
could occur after myocardial infarction or after administra-
tion of antihypertensive agents, nitrates, beta-blockers or 
calcium channel antagonists. To date, the effects of nor-
JACC Vol 7. No 6 
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triptyline on malignant ventricular arrhythmias have not been 
tested; this study in patients with benign ventricular ar-
rhythmias indicates a rationale for evaluating this agent in 
patients with malignant arrhythmias undergoing electro-
physiologic testing. 
We gratefully acknowledge the cooperation of the patients and staff of the 
General Clinical Research Center of the Presbyterian Hospital m the City 
of New York. 
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